CN113956227A - 黄酮类化合物及其合成方法和用途 - Google Patents

黄酮类化合物及其合成方法和用途 Download PDF

Info

Publication number
CN113956227A
CN113956227A CN202010701196.2A CN202010701196A CN113956227A CN 113956227 A CN113956227 A CN 113956227A CN 202010701196 A CN202010701196 A CN 202010701196A CN 113956227 A CN113956227 A CN 113956227A
Authority
CN
China
Prior art keywords
och
compound
dmso
nmr
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010701196.2A
Other languages
English (en)
Inventor
谢集照
邱莉
李雪华
谢云峰
邹录惠
徐焕基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangxi Medical University
Original Assignee
Guangxi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangxi Medical University filed Critical Guangxi Medical University
Priority to CN202010701196.2A priority Critical patent/CN113956227A/zh
Publication of CN113956227A publication Critical patent/CN113956227A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/322,3-Dihydro derivatives, e.g. flavanones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06Benzopyran radicals
    • C07H17/065Benzo[b]pyrans
    • C07H17/07Benzo[b]pyran-4-ones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

半合成黄酮类化合物及其抗炎用途。本发明属于医药技术领域,具体是天然产物之衍生物的合成及其在抗炎方面的应用,更具体的是黄酮类化合物的合成方法和在抗炎的用途。本发明以橙皮素为原料,合成了黄酮醇苷元,最后通过脱苄基与乙酰基反应合成黄酮苷。共合成了32个黄酮化合物,包括14个黄酮苷元和18个黄酮苷,其中有15个已知化合物和17个未见报道的化合物。部分化合物表现出较好的体外抗炎活性,有可能成为抗炎药物或先导化合物。

Description

黄酮类化合物及其合成方法和用途
技术领域
本发明属于医药技术领域,具体是天然产物之衍生物的合成及其在抗癌方面的应用。
背景技术
黄酮类化合物是一类具有15个碳原子组成的天然有机化合物(C6-C3-C6),骨架中含两个苯环,两个苯环由一个C3部分桥连,C3部分可以是脂肪链,也可以与C6部分形成五元或六元氧杂环。黄酮类化合物广泛存在食物和药物中,是许多天然药用植物中的主要活性成分之一,具有广泛的生物活性,如抗炎、抗氧化、抗肿瘤、保护心血管、抗菌、降血糖等药理作用。黄酮类化合物不仅结构多样,而且不同类型的化合物表现出不同的生物活性和功能。
据报道,全国每年产生柑橘类皮渣1000多万吨,约含类黄酮1万吨,其中二氢黄酮类化合物橙皮苷、橙皮素含量较高,分别约为2.9%和1.0%,其具有抗炎、抗氧化、抗肿瘤、保护心血管、免疫调节等多种生物活性。然而,橙皮苷、橙皮素因水溶性较差,生物利用度低等缺点,使其不能发挥其药理作用,限制了开发其潜在的药用价值。在对天然黄酮类化合物的研究开发利用过程中,将分布广泛、含量较高、活性低的天然黄酮类化合物半合成为含量较低、生理活性更强的黄酮类化合物、药物或先导化合物,是一种对天然黄酮类化合物资源的合理利用,同时,具有合成步骤少、生产成本低的优点,对黄酮类化合物工业上的开发具有重要意义。
乳腺癌是女性最常见的恶性肿瘤之一,其发病率在女性恶行肿瘤中居于前列。根据受体类型不同,乳腺癌可分为四种亚型:Luminal A、Luminal B、HER2过表达以及三阴型。其中,三阴型乳腺癌(TNBC)是缺乏雌激素受体(ER),孕激素受体(PR)和人表皮生长因子受体2(HER2)的表达,占所有乳腺癌类型的15%~20%。但是因其恶性程度高、侵袭力强、易复发、易转移、预后差,其被认为是乳腺癌中最凶险的类型。因此发掘具有抗三阴性乳腺癌活性的药物,并寻找相应的作用靶点具有重要的研究意义。黄酮类化合物具有广泛的生物活性,其中抗肿瘤活性有较多报道,有可能成为抗三阴型乳腺癌药物或先导化合物。
本发明以橙皮素为原料半合成其衍生物,并进行体外抗人三阴性乳腺癌活性实验。
发明内容
本发明的目的是探索以橙皮素为原料半合成其衍生物,探寻有可能成为抗三阴型乳腺癌药物或先导化合物。
本发明解决上述技术问题的技术方案如下:
以橙皮素为原料,经选择性甲基化、氧化、苄基化等反应步骤共合成了苄基保护黄酮醇苷元(合成路线图如附图1所示),然后在DMF/K2CO3条件下,与全乙酰化溴代糖进行糖苷缩合反应,最后通过脱苄基与乙酰基反应合成黄酮苷(合成路线图如附图2所示)。共合成了32个黄酮化合物,包括14个黄酮苷元和18个黄酮苷,其中有15个已知化合物和17个新化合物(结构如表1所示)。
溴代-2,3,4,6-四-O-乙酰基-α-D-葡萄糖1p、溴代-2,3,4,6-四-O-乙酰基-α-D-半乳糖1s的制备方法:先将葡萄糖或半乳糖的羟基全部乙酰化,再在红磷和溴的条件下,将乙酰基糖的异头碳溴化的一锅法合成(合成路线如附图3与附图4所示)。
表1中间体与目标化合物(标有*为未见报道的化合物)
Figure BSA0000214446230000031
Figure BSA0000214446230000041
Figure BSA0000214446230000051
Figure BSA0000214446230000061
Figure BSA0000214446230000071
Figure BSA0000214446230000081
Figure BSA0000214446230000091
Figure BSA0000214446230000101
附图说明
图1为黄酮苷元的合成路线图
图2为黄酮苷的合成路线图
图3为溴代-2,3,4,6-四-O-乙酰基-α-D-葡萄糖的合成路线图
图4为溴代-2,3,4,6-四-O-乙酰基-α-D-半乳糖的合成路线图
具体实施方式
下面结合实施例对本发明作进一步描述。
实施例1
化合物1a的合成
橙皮素(3.5g,11.6mmol)溶于350mL干燥无水丙酮中,再加入无水碳酸钾(1.6g,11.6mol),加热回流搅拌1.5h后缓慢滴加碘甲烷(1.0mL,15.4mmol),加热回流17h,滤除无水碳酸钾,蒸去丙酮,得黄色粉末粗品3.8g,经硅胶柱层析(环己烷/乙酸乙酯=2∶1,体积比,其余同),得黄色针晶固体1a(2.75g,产率75.5%)和化合物2a(206mg,产率5.6%)。
化合物1a:m.p.161~162℃;1H-NMR(DMSO-d6,600MHz)δ:12.10(s,1H,5-OH),9.10(s,1H,3′-OH),6.93(d,J=6.0,1H,H-5′),6.92(s,1H,H-2′),6.86(dd,J=8.4,1.8Hz,1H,H-6′),6.10(d,J=1.8Hz,1H,H-6),6.07(d,J=2.4Hz,1H,H-8),5.48(dd,J=12.6,3.0Hz,1H,H-2),3.78(s,3H,7-OCH3),3.76(s,3H,4′-OCH3),3.24(dd,J=16.2,12.0Hz,1H,H-3b),2.72(dd,J=17.4,3.0Hz,1H,H-3a)。13C-NMR(DMSO-d6,150MHz)δ:196.8(C-4),167.4(C-7),163.2(C-5),162.7(C-9),147.9(C-4),146.5(C-3),131.0(C-1′),117.7(C-6′),114.1(C-5′),111.9(C-2′),102.6(C-10),94.6(C-6),93.8(C-8),78.4(C-2),55.9(7-OCH3),55.7(4′-OCH3),42.1(C-3);ESI-MS m/z:315[M-H]-,317[M+H]+
化合物2a:m.p.163~164℃;1H-NMR(DMSO-d6,600MHz)δ:12.09(s,1H,5-OH),7.11(d,J=1.8Hz,1H,H-5′),7.01(dd,J=7.8,1.8Hz,1H,H-2′),6.95(d,J=7.8Hz,1H,H-6′),6.10(d,J=1.8Hz,1H,H-6),6.06(d,J=2.4Hz,1H,H-8),5.51(dd,J=12.6,3.0Hz,1H,H-2),3.76(s,3H,7-OCH3),3.74(s,3H,4-OCH3),3.73(s,3H,4′-OCH3),3.36(t,J=17.4Hz,1H,H-3b),2.74(dd,J=17.4,3.0Hz,1H,H-3a)。13C-NMR(DMSO-d6,150MHz)δ:196.9(C-4),167.5(7-C),163.2(C-5),162.8(C-9),149.1(C-4),148.7(C-3),130.8(C-1′),119.3(C-6′),111.5(C-5′),110.6(C-2′),102.6(C-10),94.7(C-6),93.9(C-8),78.7(2-C),56.0(4′-OCH3),55.6(2C,7,3′-OCH3),42.2(3-C);ESI-MS m/z:329[M-H]-,331[M+H]+
实施例2
化合物1b的合成
化合物1a(2.5g,7.9mmol)溶于40mL干燥吡啶中,再加入碘单质(2.4g,7.5mmol),90℃条件下反应,TLC跟踪反应进程,原料点消失停止反应,冷却至室温后,在剧烈搅拌下缓慢加入冰水,析出棕黑色固体,抽滤,滤饼用3%稀盐酸洗至无吡啶味,再用饱和硫代硫酸钠除去未反应的碘单质,烘干得黄色粗品,无水乙醇重结晶得黄色针晶2.0g,产率93.9%。m.p.162~163℃;1H-NMR(DMSO-d6,600MHz)δ:12.92(s,1H,5-OH),9.44(s,1H,3′-OH),7.56(dd,J=8.4,2.4Hz,1H,H-6′),7.45(d,J=2.4Hz,1H,H-2′),7.09(d,J=8.4Hz,1H,H-5′),6.81(s,1H,3-H),6.75(d,J=1.8Hz,1H,H-8),6.37(d,1H,J=2.4Hz,H-6),3.86(s,6H,7,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:181.9(C-4),165.2(C-2),163.9(C-7),161.2(C-5),157.3(C-9),151.3(C-4′),146.8(C-3′),122.9(C-1′),118.8(C-6′),113.1(C-2′),112.1(C-5′),104.7(C-10),103.7(C-3),98.0(C-6),92.7(C-8),56.1(4′-OCH3),55.8(7-OCH3);ESI-MS m/z:313[M-H]-,315[M+H]+
实施例3
化合物1c的合成
橙皮素(5.0g,15.8mmol)溶于80mL干燥吡啶中,再加碘单质(4.8g,15mmol),90℃条件下反应,TLC跟踪反应进程,原料点消失停止反应,冷却到室温后,在剧烈搅拌下缓慢加入冰水,析出棕黑色固体,抽滤,滤饼用3%稀盐酸洗至无吡啶味,再用饱和硫代硫酸钠除去未反应的碘单质,烘干得黄色粗品,无水乙醇重结晶得黄色粉末4.5g,产率90.5%。m.p.254~255℃;1H-NMR(DMSO-d6,600MHz)δ:12.73(s,1H,5-OH)7.46(s,1H,H-2′),7.23(d,J=8.4Hz,1H,6′-H),6.92(d,J=8.4Hz,1H,H-5′),6.30(s,1H,H-3),5.92(s,1H,H-8),5.55(s,1H,H-6),3.79(3H,s,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:179.1(C-4),177.4(C-2),161.1(C-7),161.0(C-5),158.3(C-9),150.7(C-4′),149.2(C-3′),124.0(C-1′),115.7(C-6′),112.7(C-2′),112.0(C-5′),102.7(C-10),102.1(C-3),98.7(C-6),96.7(C-8),55.5(4′-OCH3);ESI-MS m/z:299[M-H]-,301[M+H]+
实施例4
化合物1d的合成
第一种合成路径:
化合物1c(2.0g,6.67mmol)溶于350mL干燥无水丙酮中,再加入无水碳酸钾(2.0g,14.5mol),加热回流搅拌1.5h后缓慢滴加碘甲烷(1.3mL,20.0mmol),加热回流17h,滤除无水碳酸钾,蒸去丙酮,得黄色粉末粗品2.5g,过硅胶柱层析(环己烷/乙酸乙酯=2∶1),得黄色粉末1.9g,产率87%。
第二种合成路径:
化合物2a(200mg,0.6mmol)溶于5mL干燥吡啶中,再加入碘单质(200mg,0.62mmol),90℃条件下反应,TLC跟踪反应进程,原料点消失停止反应,冷却到室温后在剧烈搅拌下缓慢加入冰水,析出棕黑色固体,抽滤,滤饼用3%稀盐酸洗至无吡啶味,再用饱和硫代硫酸钠除去未反应的碘单质,烘干得粗品,无水乙醇重结晶得黄色粉末160mg,产率84%。m.p.164~165℃;1H-NMR(DMSO-d6,600MHz)δ:12.90(s,1H,5-OH),7.72(dd,J=8.4,1.8Hz,1H,H-6′),7.58(d,J=1.8Hz,1H,H-2′),7.14(d,J=9.0Hz,1H,H-5′),7.03(s,1H,H-3),6.81(d,J=2.4Hz,1H,H-8),6.38(d,J=1.8Hz,1H,H-6),3.89(3H,s,4′-OCH3),3.88(s,3H,3′-OCH3),3.86(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:182.0(C-4),165.2(C-2),163.6(C-7),161.1(C-5),157.3(C-9),152.2(C-4′),149.0(C-3′),122.7(C-1′),120.1(C-6′),111.6(C-5′),109.4(C-2′),104.7(C-10),104.0(C-3),98.0(C-6),92.7(C-8),56.1(7-OCH3),55.9(4′-OCH3),55.7(3′-OCH3);ESI-MS m/z:327[M-H]-,329[M+H]+
实施例5
化合物1e的合成
化合物1b(2.0g,9.3mmol)溶于100mL干燥无水丙酮中,再加入无水碳酸钾(13.0g,94.2mmol),加热回流搅拌1.5h后缓慢滴加溴化苄(2.6mL,20.0mmol),继续回流反应,TLC跟踪反应进程,原料点消失停止反应,冷却至室温,滤除碳酸钾,减压回收溶剂,得黄色粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得黄色粉末2.1g,产率67.8%。1H-NMR(DMSO-d6,600MHz)δ:7.29-7.66(m,12H,5,3′-Bn-Ar,H-2′,H-6′),7.12(d,J=14.4Hz,1H,5′-H),6.85(d,J=2.4Hz,1H,H-8),6.73(s,1H,H-3),6.59(d,J=1.8Hz,1H,H-6),5.22(d,J=4.2Hz,4H,5,3′-Bn-CH2),3.88(s,3H,4′-OCH3),3.84(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:175.7(C-4),163.5(C-2),159.7(C-7),159.1(C-5),158.9(C-9),151.9(C-4′),148.0(C-3′),126.9-136.9(12C,5,3′-O-Bn-Ar),123.0(C-1′),119.7(C-6′),111.9(C-2′),110.8(C-5′),108.7(C-10),107.1(C-3),97.7(C-6),93.7(C-8),70.2(3′-O-Bn-CH2),69.8(7-O-Bn-CH2),56.0(4′-OCH3),55.8(7-OCH3);ESI-MS m/z:493[M-H]-,495[M+H]+
实施例6
化合物1f的合成
化合物1d(2.0g,5.89mmol)溶于100mL无水丙酮中,再加入无水碳酸钾(8.0g,58.0mmol),回流搅拌1h后,缓慢滴加溴化苄(1.0mL,7.7mmol),继续加热回流,TLC跟踪反应进程,原料点消失停止反应,冷却至室温,滤除碳酸钾,减压回收溶剂,得黄色粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得浅黄色粉末1.8g,产率71.8%。1H-NMR(DMSO-d6,600MHz)δ:7.66(dd,J=1.8Hz,1H,H-6′),7.62(d,J=1.8Hz,2H,H-2′,Bn-Ar),7.31-7.43(m,4H,Bn-Ar),7.12(d,J=8.4Hz,1H,H-5′),6.89(d,J=1.8Hz,1H,H-8),6.76(s,1H,H-3),6.61(d,J=2.4Hz,1H,6-H),5.24(s,2H,5-Bn-CH2),3.90(s,3H,4′-OCH3),3.89(3H,s,3′-OCH3),3.85(3H,s,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:175.7(C-4),163.5(C-2),159.7(C-7),159.1(C-5),158.9(C-9),151.6(C-4′),149.0(C-3′),126.8-136.9(6C,Bn-Ar-C),123.1(C-1′),119.4(C-6′),111.6(C-2′),109.1(C-5′),108.7(C-10),107.1(C-3),97.7(C-6),93.7(C-8),69.8(Bn-CH2),56.0(4′-OCH3),55.9(3′-OCH3),55.7(7-OCH3);ESI-MS m/z:417[M-H]-,419[M+H]+
实施例7
化合物1g的合成
化合物1c(2.4g,7.9mmol)溶于100mL干燥的丙酮中,再加入无水碳酸钾(11g,80mmol),加热回流搅拌1h后,缓慢滴加溴化苄(3.3mL,25mmol),继续搅拌回流反应,TLC跟踪反应进程,原料点消失停止反应,冷却至室温,滤除碳酸钾,蒸去丙酮,得黄色粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得黄色固体3.0g,产率65%。m.p.153~154℃;1H-NMR(DMSO-d6,600MHz)δ:7.31-7.66(m,17H,5,7,3′-Bn-Ar,H-2′,H-6′),7.16(d,J=9.6Hz,1H,H-5′),7.00(d,J=1.8Hz,1H,H-8),6.75(s,1H,H-3),6.71(d,J=1.8Hz,1H,H-6),5.26(s,2H,3′-O-Bn-CH2),5.25(s,2H,7-O-Bn-CH2),5.24(s,2H,5-O-Bn-CH2),3.87(s,3H,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:175.6(C-4),162.5(C-2),159.6(C-7),159.0(2C,C-5,C-9),151.9(C-4′),148.0(C-3′),123.6-136.8(18C,Bn-Ar-C),123.0(C-1′),119.7(C-6′),112.0(C-2′),110.8(C-5′),108.8(C-10),107.1(C-3),94.6(C-6),91.1(C-8),70.2(3′-O-Bn-CH2),70.0(7-O-Bn-CH2),69.8(5-O-Bn-CH2),55.8(4′-OCH3);ESI-MS m/z:569[M-H]-,571[M+H]+
实施例8
化合物1h的合成
化合物1e(1.6g,3.2mmol)溶于140mL二氯甲烷/丙酮(v/v=4∶3)混合溶剂中,加200mL Na2CO3/NaHCO3缓冲溶液(Na2CO38.0g,NaHCO33.8g),在室温下剧烈搅拌,并用恒压漏斗缓慢滴加过硫酸氢钾复合盐溶液(12g,140mL),6h滴完,反应21h后,再缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL),约6h滴完,TLC监控至原料点消失,停止反应,静置分离有机相,水相用二氯甲烷(100mL×2)萃取,合并有机相,分别用饱和硫代硫酸钠(100mL×2)和饱和食盐水(100mL×2)洗涤有机相,无水硫酸钠干燥有机相,过滤,滤液中加入6mg对甲苯磺酸,继续在室温下反应2h,蒸干溶剂,得棕色粗品,二氯甲烷/甲醇重结晶得黄色粉末1.0g,产率62.0%。1H-NMR(DMSO-d6,600MHz)δ:9.16(s,1H,3-OH),7.31-7.87(m,12H,5,3′-O-Bn-Ar,H-2′,H-6′),7.15(d,J=9.0Hz,1H,H-5′),6.84(d,J=1.8Hz,1H,H-8),6.61(d,J=2.4Hz,1H,H-6),5.26(s,2H,3′-O-Bn-CH2),5.18(s,2H,5-O-Bn-CH2),3.93(s,3H,4′-OCH3),3.86(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.2(C-4),163.6(C-2),158.8(C-7),158.0(C-5),150.3(C-9),147.5(C-4′),141.6(C-3′),138.2(C-3),126.6-136.9(12C,5,3′-O-Bn-Ar),123.5(C-1′),121.2(C-6′),112.3(C-2′),111.8(C-5′),106.6(C-10),96.8(C-6),93.1(C-8),70.3(3′-O-Bn-CH2),69.8(5-O-Bn-CH2),56.0(4′-OCH3),55.6(7-OCH3);ESI-MS m/z:509[M-H]-,511[M+H]+
实施例9
化合物1i的合成
化合物1f(1.5g,3.5mmol)溶于140mL二氯甲烷/丙酮(v/v=4∶3)混合溶剂中,加200mL Na2CO3/NaHCO3缓冲溶液(8.0g Na2CO3,3.8g NaHCO3,200mL H2O),在室温下剧烈搅拌,并用恒压漏斗缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约6h滴完,反应过夜后,再缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约2h滴完,原料点消失,停止反应,静置分离有机相,水相用二氯甲烷(100mL×2)萃取,合并有机相,分别用饱和硫代硫酸钠(100mL×2)和饱和食盐水(100mL×2)洗涤有机相,无水硫酸钠干燥有机相,过滤,滤液中加入5mg对甲苯磺酸,在室温下反应2h,蒸干溶剂,得棕色固体,二氯甲烷/甲醇重结晶得黄色粉末0.97g,产率60.4%。1H-NMR(DMSO-d6,600MHz)δ:9.14(1H,s,3-OH),7.84(dd,J=8.4,1.8Hz,1H,H-6′),7.78(d,J=1.8Hz,1H,H-2′),7.70(d,J=2.8Hz,2H,5-O-Bn-Ar),7.42(t,J=15.6Hz,2H,5-O-Bn-Ar),7.33(t,J=15.0Hz,1H,5-O-Bn-Ar),7.147.70(d,J=9.0Hz,1H,H-5′),6.88(d,J=1.8Hz,1H,H-8),6.61(d,J=1.8Hz,1H,H-6),5.26(s,2H,5-O-Bn-CH2),3.91(s,3H,4′-OCH3),3.85(s,3H,3′-OCH3),3.84(3H,s,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.2(C-4),163.6(C-2),158.8(C-7),158.0(C-5),149.9(C-9),148.4(C-4′),141.8(C-3′),138.1(C-3),126.6-136.9(6C,5-O-Bn-Ar),123.6(C-1′),120.8(C-6′),111.5(C-2′),110.5(C-5′),106.6(C-10),96.8(C-6),93.1(C-8),69.8(5-O-Bn-CH2),56.0(7-OCH3),55.7(4′-OCH3),55.6(3′-OCH3),;ESI-MS m/z:433[M-H]-,435[M+H]+
实施例10
化合物1j的合成
化合物1g(2.0g,3.5mmol)溶于140mL二氯甲烷/丙酮(v/v=4∶3)混合溶剂中,加200mL Na2CO3/NaHCO3缓冲溶液(8.0g Na2CO3,3.8g NaHCO3,200mL H2O),在室温下剧烈搅拌,并用恒压漏斗缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约6h滴完,反应12h后,再缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约6h滴完,原料点消失,停止反应,静置分离有机相,水相用二氯甲烷(100mL×2)萃取,合并有机相,分别用饱和硫代硫酸钠(100mL)和饱和食盐水(100mL)洗涤有机相,无水硫酸钠干燥有机相,过滤,滤液中加入5mg对甲苯磺酸,在室温下反应2h,蒸干溶剂,得棕色油状物,无水乙醇重结晶的黄色粉末1.2g,产率58.5%。m.p.159~160℃;1H-NMR(DMSO-d6,600MHz)δ:9.16(s,1H,3-OH),7.85(s,1H,H-2′),7.30-7.68(m,16H,7,5,3′-O-Bn-Ar,H-6′),7.16(d,J=8.4Hz,1H,H-5′),6.96(s,1H,H-8),6.70(d,J=1.8Hz,1H,H-6),5.25(s,4H,7,3′-O-Bn-CH2),5.16(s,2H,5-O-Bn-CH2),3.84(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.2(C-4),162.7(C-2),158.9(C-7),157.9(C-5),150.3(C-9),147.5(C-4′),141.7(C-3′),138.2(C-3),126.6-136.9(18C,5,7,3′-O-Bn-Ar-C),123.5(C-1′),121.2(C-6′),112.2(C-2′),111.9(C-5′),106.7(C-10),97.3(C-6),94.0(C-8),70.3(3′-O-Bn-CH2),70.1(7-O-Bn-CH2),69.8(5-O-Bn-CH2),55.7(4′-OCH3),;ESI-MS m/z:585[M-H]-,587[M+H]+
实施例11
化合物1k的合成
化合物1h(51mg,0.1mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(90mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色粉末25mg,产率78%。1H-NMR(DMSO-d6,600MHz)δ:12.44(s,1H,5-OH),9.55(br s,1H,3-OH),9.32(s,1H,3′-OH),7.71(d,J=2.4H,1H,H-2′),7.68(dd,J=8.4,1.8Hz,1H,H-6′),7.08(d,J=8.4Hz,1H,H-5′),6.71(d,J=1.8Hz,1H,H-8),6.34(d,J=2.4Hz,1H,H-6),3.85(s,3H,4′-OCH3),3.84(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:176.1(C-4),165.0(C-2),160.4(C-7),156.1(C-5),149.4(C-9),146.8(C-4′),146.2(C-3′),136.5(3-C),123.4(C-1′),119.8(C-6′),114.7(C-2′),111.8(C-5′),104.1(C-10),97.5(C-6),91.9(C-8),56.0(4′-OCH3),55.6(7-OCH3);ESI-MS m/z:329[M-H]-,331[M+H]+
实施例12
化合物1l的合成
化合物1i(50mg,0.12mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(90mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色粉末34mg,产率85%。1H-NMR(DMSO-d6,600MHz)δ:12.40(s,1H,5-OH),9.64(s,1H,3-OH),7.84(d,J=8.4Hz,1H,H-6′)7.75(s,1H,H-2′),7.13(d,J=8.4Hz,1H,H-5′),6.78(s,1H,H-8),6.34(s,1H,H-6),3.84(s,6H,3′,4′-OCH3),3.82(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:176.1(C-4),165.0(C-2),160.4(C-7),156.2(C-5),150.5(C-9),148.4(C-4′),146.6(C-3′),1366(C-3),123.2(C-1′),121.6(C-6′),111.5(C-2′),110.9(C-5′),104.1(C-10),97.6(C-6),92.2(C-8),56.1(4′-OCH3),55.7(3′-OCH3),55.6(7-OCH3);ESI-MS m/z:323[M-H]-,325[M+H]+
实施例13
化合物1m的合成
化合物化1j(50mg,0.08mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(90mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色粉末23mg,产率84%。m.p.143~144℃;1H-NMR(DMSO-d6,600MHz)δ:12.46(s,1H,5-OH),7.75(d,J=7.2Hz,1H,H-5′),7.69(dd,J=8.4,1.8Hz,1H,H-6′),7.47(d,J=1.8Hz,1H,H-2′),6.94(d,J=1.8Hz,1H,H-8),6.19(d,J=1.8Hz,1H,H-6),3.84(s,3H,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:176.0(C-4),165.0(C-2),160.4(C-7),156.2(C-5),159.3(C-9),146.3(C-4′),146.2(C-3′),136.1(C-3),123.4(C-1′),119.7(C-6′),114.6(C-2′),111.8(C-5′),103.1(C-10),98.2(C-6),93.4(C-8),55.6(4′-OCH3)ESI-MS m/z:315[M-H]-,317[M+H]+
实施例14
化合物1的合成
化合物1h(120mg,0.23mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(110mg,0.80mmol),全乙酰化溴代葡萄糖(186mg,0.46mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得黄色固体112.6mg,产率60.0%。1H-NMR(DMSO-d6,600MHz)δ:7.81(d,J=1.8Hz,1H,H-2′),7.73(dd,J=8.4,2.4Hz,H-6′),7.63(d,J=7.2Hz,H-2′),7.32-7.63(m,10H,Bn-Ar),7.13(d,J=9.0Hz,1H,H-5′),6.80(d,J=1.8Hz,1H,H-8),6.62(d,J=2.4Hz,1H,H-6),5.72(d,J=7.8Hz,1H,H-1″),5.43(t,J=13.2Hz,1H,H-6″),5.24(d,J=6.6Hz,2H,3′-O-Bn-CH2),5.20(d,2H,J=4.2Hz,5-O-Bn-CH2),5.05(m,1H,H-6″),4.93(m,1H,H-5″),3.98(m,2H,,H-2″,H-3″),3.89(s,3H,4′-OCH3),3.86(s,3H,7-OCH3),3.93-3.84(m,1H,H-5″),2.08(s,3H,COCH3),1.95(s,6H,CH3CO),1.73(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.6,169.5,169.4,169.3(4C,Ac-CO×4),163.8(C-7),159.1(C-2),158.2(C-5),153.4(C-9),151.1(C-4′),147.0(C-3′),136.9(C-3),127.0-136.7(10C,Bn-Ar),122.4(C-1′),122.2(C-6′),113.8(C-2′),111.3(C-5′),108.5(C-10),98.3(C-1″),97.5(C-6),93.3(C-8),71.7(3′-O-Bn-CH2),71.6(5-O-Bn-CH2),70.4(C-3″),70.2(C-2″),70.0(C-4″),67.9(C-5″),61.1(C-6″),56.1(4′-OCH3),55.7(7-OCH3),20.6,20.4,20.3,20.0(4C,Ac-CH3);ESI-MS m/z:839[M-H]-,841[M+H]+
实施例15
化合物2的合成
化合物1i(100mg,0.23mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(220mg,1.6mmol),全乙酰化溴代葡萄糖(186mg,0.46mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得116.0mg白色固体化合物,产率65.8%。1H-NMR(DMSO-d6,600MHz)δ:7.76(d,J=1.8Hz,1H,H-2′),7.69(dd,J=9.0,2.4Hz,1H,H-6′),7.63(d,J=7.2Hz,2H,Bn-Ar),7.42(t,J=15.0Hz,2H,Bn-Ar),7.33(t,J=15Hz,1H,Bn-Ar),7.10(d,J=8.4Hz,1H,H-5′),6.85(d,J=2.4Hz,1H,H-8),6.62(d,J=2.4Hz,1H,H-6),5.74(d,J=7.8Hz,1H,H-1″),5.43(t,J=19.8Hz,1H,H-6″),5.24(d,J=6.6Hz,2H,5-O-Bn-CH2),5.02(m,1H,H-6″),4.90(m,1H,H-5″),3.99(m,1H,H-2″,H-3″),3.89(s,3H,4′-OCH3),3.88(s,3H,3′-OCH3),3.84(s,3H,7-OCH3),3.82(m,1H,H-5″),2.07(s,3H,CH3CO),1.96(s,3H,CH3CO),1.95(s,3H,CH3CO),1.79(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.6,169.5,169.4,169.3(4C,Ac-CO),163.8(C-7),159.1(C-2),158.2(C-5),153.4(C-9),150.8(C-4′),147.9(C-3′),136.7(C-3),127.0-135.3(5C,5-O-Bn-Ar),122.3(C-1′),121.8(C-6′),112.2(C-2′),111.0(C-5′),108.5(C-10),98.4(C-1″),97.5(C-6),93.4(C-8),71.7(5-O-Bn-CH2),71.6(C-3″),70.4(C-2″),70.0(C-4″),67.8(C-5″),61.0(C-6″),56.1(4′-OCH3),55.6(3′-OCH3),55.5(7-OCH3),20.5,20.4,20.3,20.0(4C,Ac-CH3);ESI-MS m/z:763[M-H]-,765[M+H]+
实施例16
化合物3的合成
化合物1j(180mg,0.32mmol)溶于干燥的DMF(10mL)中,加K2CO3(330mg,2.4mmol),全乙酰化溴代葡萄糖(260mg,0.64mmol),在室温氮气保护下反应24h后,加30mL H2O稀释猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(40mL×3),饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/V乙酸乙酯=2∶1)得淡黄色固体148.5mg,产率53.4%。1H-NMR(DMSO-d6,600MHz)δ:7.82(d,J=2.4Hz,1H,H-2′),7.72(dd,J=8.4,2.4Hz,1H,H-6′),7.62(d,J=7.2Hz,2H,Bn-Ar),7.52(d,J=7.2Hz,2H,Bn-Ar),7.49(d,J=7.2Hz,2H,Bn-Ar),7.32-7.44(m,9H,Bn-Ar),7.14(d,J=9.0Hz,1H,H-5′),6.94(d,J=2.4Hz,1H,H-8),6.73(d,J=1.8Hz,1H,H-6),5.74(d,J=7.8Hz,1H,H-1″),5.44(t,J=19.2Hz,1H,H-6″),5.25(m,4H,7,3′-O-Bn-CH2),5.20(d,J=7.8Hz,2H,5-O-Bn-CH2),5.04-5.07(m,1H,H-6″),4.91-4.95(m,1H,H-5″),3.94-3.98(m,2H,H-2″,H-3″),3.86(s,3H,4′-OCH3),3.81-3.84(m,1H,H-4″),2.08(s,3H,CH3CO),1.96(s,6H,CH3CO),1.73(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.6,169.5,169.4,169.3(4C,Ac-CO),162.8(C-7),159.1(C-2),158.1(C-5),153.4(C-9),151.2(C-4′),147.0(C-3′),136.85(C-3),126.9-136.7(15C,Bn-Ar),122.4(C-1′),122.2(C-6′),113.8(C-2′),111.3(C-5′),108.6(C-10),98.3(C-1″),97.9(C-6),94.2(C-8),71.7,71.6,70.4(3C,Bn-CH2),70.2(C-3″),70.1(C-2″),70.0(C-4″),67.9(C-6″),61.1(C-5″),55.7(4′-OCH3),20.6,20.4,20.3,20.0(4C,Ac-CH3);ESI-MS m/z:915[M-H]-,917[M+H]+
实施例17
化合物4的合成
化合物1h(100mg,0.20mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(193mg,1.4mmol),全乙酰化溴代半乳糖(160mg,0.40mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得淡黄色固体108.0mg,产率69.0%。1H-NMR(DMSO-d6,600MHz)δ:7.95(d,J=2.4Hz,1H,H-2′),7.72(dd,J=8.4,1.8Hz,1H,H-6′),7.63(d,J=7.8Hz,2H,Bn-Ar),7.53(d,J=7.2Hz,2H,Bn-Ar),7.32-7.43(m,6H,Bn-Ar),7.10(d,J=9.0Hz,1H,H-5′),6.81(d,J=1.8Hz,1H,H-8).6.61(d,J=2.4Hz,1H,H-6),5.69(d,J=7.8Hz,1H,H-1″),5.26-5.36(m,2H,H-3″,H-5″),5.23(d,J=1.8Hz,2H,3′-O-Bn-CH2),5.18-5.20(m,3H,5-O-Bn-CH2,H-2″),4.19-4.21(t,J=12.6Hz,1H,H-4″),3.92-4.03(m,1H,H-6″),3.89(s,3H,4′-OCH3),3.85(s,3H,7-OCH3),3.80-3.84(m,1H,H-6″),2.10(s,3H,CH3CO),1.92(s,3H,CH3CO),1.79(s,3H,CH3CO),1.75(s,3H,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.4(C-4),169.8,169.7,169.6,169.42(4C,Ac-CO),163.8(C-7),159.1(C-2),153.0(C-5),151.2(C-4′),147.0(C-3′),136.9(C-3),127.0-136.7(12C,Bn-Ar),122.3(C-1′),122.0(C-6′),114.0(C-2′),111.3(C-5′),108.5(C-10),98.9(C-1″),97.5(C-6),93.3(C-8),70.2(7-O-Bn-CH2),70.0(2C,5,4′Bn-CH2),70.0(2C,C-2″,C-3″),69.2(C-4″),67.2(C-5″),60.7(C-6″),56.1(4′-OCH3),55.7(7-OCH3),20.7,20.4,20.2,19.9(4C,Ac-CH3);ESI-MS m/z:839[M-H]-,841[M+H]+
实施例18
化合物5的合成
化合物1i(100mg,0.23mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(220mg,1.6mmol),全乙酰化溴代半乳糖(186mg,0.46mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得白色固体112.7mg,产率64.0%。1H-NMR(DMSO-d6,600MHz)δ:7.91(d,J=1.8Hz,1H,H-2′),7.65(dd,J=8.4,1.8Hz,1H,H-6′),7.60(d,J=7.2Hz,2H,Bn-Ar),7.42(t,J=8.4Hz,2H,Bn-Ar),7.33(t,J=15Hz,1H,Bn-Ar),7.07(d,J=8.4Hz,1H,H-5′),6.84(d,J=1.8Hz,1H,H-8),6.60(d,J=1.8Hz,1H,H-6),5.70(d,J=8.4Hz,1H,H-1″),5.33(m,1H,H-5″),5.15-5.22(m,5H,5-O-Bn-CH2,H-2″,H-3″,H-4″),4.19(m,2H,H-6″),3.91(s,3H,4′-OCH3),3.87(s,3H,3′-OCH3),3.83(s,3H,7-OCH3),2.08(s,6H,CH3CO),1.92(s,3H,CH3CO),1.75(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.9,169.6,169.6,169.5(4C,Ac-CO),163.8(C-7),159.1(C-2),158.2(C-5),153.2(C-9),150.8(C-4′),147.8(C-3′),136.8(C-3),127.0-135.3(5C,Bn-Ar),122.33(C-1′),121.3(C-6′),112.4(C-2′),111.0(C-5′),108.5(C-10),98.8(C-1″),97.5(C-6),93.3(C-8),70.3(5-O-Bn-CH2),70.0(C-2″),69.9(C-3″),69.1(C-4″),67.2(C-5″),60.7(C-6″),56.1(4′-OCH3),55.7(3′-OCH3),55.5(7-OCH3),20.7,20.4,20.3,20.2(4C,Ac-CH3);ESI-MS m/z:763[M-H]-,765[M+H]+
实施例19
化合物6的合成
化合物1j(200mg,0.36mmol)溶于干燥的DMF(10mL)中,加K2CO3(350mg,2.54mmol),全乙酰化溴代半乳糖(290mg,0.71mmol),在室温氮气保护下反应24h后,加30mL H2O稀释猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(40mL×3),饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得白色固体182mg,产率65.5%。1H-NMR(DMSO-d6,600MHz)δ:7.96(s,1H,H-2′),7.72(dd,J=8.4,1.8Hz,1H,H-6′),7.62(d,J=7.2Hz,2H,Bn-Ar),7.53(d,J=7.2Hz,2H,Bn-Ar),7.47(d,J=7.2Hz,2H,Bn-Ar),7.30-7.42(m,9H,Bn-Ar),7.12(d,J=9.0Hz,1H,H-5′),6.94(s,1H,H-8),6.70(s,1H,H-6),5.70(d,J=7.8Hz,1H,H-1″),5.26-5.35(m,2H,H-3″,H-5″),5.17-5.26(m,6H,5,3′-O-BnCH2,H-2″,H-4″),4.19(t,J=13.2Hz,1H,H-6″),3.85(s,3H,4′-OCH3),3.82-3.84(m,1H,H-6″),2.10(s,3H,CH3CO),1.92(s,3H,CH3CO),1.78(s,3H,CH3CO),1.74(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.36(C-4),169.81,169.70,169.57,169.43(4C,Ac-CO),162.83(C-7),159.13(C-2),158.08(C-5),153.03(C-4′),151.20(C-3′),146.99(C-10),136.87(C-3),126.94-136.75(15C,Bn-Ar-C),122.32(C-1′),121.99(C-6′),114.03(C-2′),111.33(C-5′),108.60(C10),98.89(C-1″),97.92(C-6),94.19(C-8),70.2(5-O-Bn-CH2),70.1(3′-O-Bn-CH2),70.0(5-O-Bn-CH2),70.0(C-2″),70.0(C-3″),69.2(C-4″),67.2(C-5″),60.7(C-6″),55.7(4′-OCH3),20.7,20.4,20.2,19.9(4C,Ac-CH3);ESI-MS m/z:915[M-H]-,917[M+H]+
实施例20
化合物7的合成
化合物1(96mg,0.114mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物74mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),9.41(s,1H,3′-OH),7.63(d,J=2.4Hz,1H,H-2′),7.60(dd,J=8.4,1.8Hz,1H,H-6′),7.06(d,J=8.4Hz,1H,H-5′),6.74(d,J=2.4Hz,1H,H-8),6.38(d,J=2.4Hz,1H,H-6),5.70(d,J=7.8Hz,1H,H-1″),5.36(t,J=19.2Hz,1H,H-6″),5.13(t,J=17.4Hz,1H,H-6″),5.01(t,J=19.2Hz,1H,H-5″),3.87-3.98(m,3H,H-2″,H-3″,H-4″),3.85(s,3H,4′-OCH3),3.84(s,3H,7-OCH3),2.02(s,3H,CH3CO),1.96(s,3H,CH3CO),1.95(s,3H,CH3CO),1.81(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.7,169.5,169.3,169.3(4C,Ac-CO),165.4(C-7),160.8(C-2),157.2(C-5),156.3(C-9),150.4(C-4′),146.0(C-3′),133.2(C-3),121.9(C-1′),121.1(C-6′),116.1(C-2′),111.3(C-5′),105.0(C-10),98.6(C-1″),98.1(C-6),92.4(C-8),71.9(C-3″),71.4(C-2″),70.6(C-5″),67.8(C-4″),61.0(C-6″),56.2(4′-OCH3),55.6(7-OCH3),20.5,20.4,20.3,20.1(4C,Ac-CH3);ESI-MS m/z:659[M-H]-,661[M+H]+
实施例21
化合物8的合成
化合物2(90mg,0.118mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了12h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物78.8mg,产率99%。1H-NMR(DMSO-d6,600MHz)δ:12.46(s,5-OH),7.74(d,J=2.4Hz,1H,H-2′),7.69(dd,J=8.4,1.8Hz,1H,H-6′),7.13(d,J=9.0Hz,1H,H-5′),6.80(d,J=1.8Hz,1H,H-8),6.40(d,J=1.8Hz,1H,H-6),5.72(d,J=8.4Hz,1H,H-1″),5.38(t,J=19.2Hz,1H,H-6″),5.02(t,J=18.0Hz,1H,H-6″),4.90(t,J=17.8Hz,1H,H-5″),3.97-4.00(m,2H,H-2″,H-3″),3.88(s,3H,4′-OCH3),3.87(s,3H,3′-OCH3),3.84(s,3H,7-OCH3),3.80-3.84(m,1H,H-4″),2.03,1.95,1.79(s,12H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:176.7(C-4),169.4,169.2,169.1,169.0(4C,Ac-CO),165.13(C-7),160.6(C-2),156.8(C-5),156.1(C-9),151.1(C-4′),147.6(C-3′),133.0(C-3),122.2(C-1′),121.6(C-6′),112.0(C-2′),110.8(C-5′),104.8(C-10),98.4(C-1″),97.8(C-6),92.4(C-8),71.4(C-3″),71.1(C-2″),70.4(C-5″),67.4(C-4″),60.7(C-6″),55.9(4′-OCH3),55.4(3′-OCH3),55.3(7-OCH3),20.2,20.1,20.0,19.8(4C,Ac-CH3);ESI-MS m/z:673[M-H]-,675[M+H]+
实施例22
化合物9的合成
化合物3(225mg,0.273mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物169mg,产率96%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),10.92(br-s,1H,7-OH),9.40(s,1H,3′-OH),7.57(d,J=1.8Hz,1H,H-2′),7.55(dd,J=9.0,2.4Hz,1H,H-6′),7.02(d,J=8.4Hz,1H,H-5′),6.41(d,J=1.8Hz1H,H-8),6.19(d,J=1.8Hz,1H,H-6),5.66(d,J=7.8Hz,1H,H-1″),5.34(t,J=19.2Hz,1H,H-6″),5.11(t,J=18.0Hz,1H,H-6″),4.99(t,J=18.6Hz,1H,H-5″),3.91-3.95(m,2H,H-2″,H-3″),3.84-3.86(m,1H,H-4″),3.82(s,3H,4′-OCH3),2.00,1.95,1.94,1.80(s,each 3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:176.8(C-4),169.8,169.5,169.3,169.3(4C,Ac-CO),164.4(C-7),161.2(C-2),156.8(C-5),156.4(C-9),150.3(C-4′),145.9(C-3′),133.0(C-3),122.0(C-1′),121.0(C-6′),115.9(C-2′),111.3(C-5′),104.0(C-10),98.8(C-1″),98.6(C-6),93.8(C-8),71.9(C-3″),71.4(C-2″),70.5(C-5″),67.8(C-4″),61.0(C-6″),55.6(4′-OCH3),20.5,20.4,20.3,20.1(4C,Ac-CH3);ESI-MS m/z:645[M-H]-,647[M+H]+
实施例23
化合物10的合成
化合物4(100mg,0.119mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去pd/C,浓缩回收溶剂得黄色油状物77mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.47(s,1H,5-OH),9.22(s,1H,3′-OH),7.62(dd,J=8.4,2.4Hz,1H,H-6′),7.52(d,J=1.8Hz,1H,H-2′),7.03(d,J=8.4Hz,H-5′),6.71(d,J=2.4Hz,1H,H-8),6.35(d,J=1.8Hz,1H,H-6),5.61(d,J=7.2Hz,1H,H-1″),5.22-5.24(m,1H,H-5″),5.16-5.20(m,3H,H-2″,H-3″,H-,4″),3.84(s,3H,4′-OCH3),3.83(s,3H,7-OCH3),3.79-3.82(m,2H,H-6″),2.10(s,3H,CH3CO),2.02(s,3H,CH3CO),1.90(s,3H,CH3CO),1.75(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.1(C-4),169.9,169.6,169.5,169.4(4C,Ac-CO),165.3(C-7),160.9(C-2),157.2(C-5),156.4(C-9),150.4(C-4′),146.0(C-3′),133.3(C-3),122.2(C-1′),121.5(C-6′),116.0(C-2′),111.2(C-5′),105.0(C-10),98.9(C-1″),98.1(C-6),92.4(C-8),70.2(2C,C-2″,C-3″),69.2(C-4″),67.1(C-5″),60.9(C-6″),56.2(4′-OCH3),55.7(7-OCH3),20.6,20.4,20.4,20.2(4C,Ac-CH3);ESI-MS m/z:659[M-H]-,661[M+H]+
实施例24
化合物11的合成
化合物5(90mg,0.118mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物78mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.51(s,5-OH),7.91(d,J=1.8Hz,1H,H-2′),7.68(dd,J=8.4,1.8Hz,1H,H-6′),7.12(d,J=9.0Hz,1H,H-5′),6.78(d,J=8.4Hz,1H,H-8),6.37(d,J=15Hz,1H,H-6),5.74(t,J=13.8Hz,1H,H-1″),5.31(m,1H,H-5″),5.22-5.25(m,2H,H-3″,H-2″),4.24(m,1H,H-4″),3.92(s,3H,4′-OCH3),3.86(s,6H,7,3′-OCH3),3.36-3.41(m,1H,H-6″),3.26-3.31(m,1H,H-6″),2.09,2.06,1.93,1.77(s,each3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.8,169.6,169.5,169.5(4C,Ac-CO),165.4(C-7),160.8(C-2),156.8(C-5),156.3(C-9),151.4(C-4′),147.9(C-3′),133.2(C-3),122.0(C-1′),121.9(C-6′),112.6(C-2′),111.1(C-5′),105.0(C-10),99.0(C-1″),98.1(C-6),92.6(C-8),70.3(C-2″),69.9(C-3″),68.9(C-4″),67.1(C-5″),60.7(C-6″),56.2(4′-OCH3),55.7(3′-OCH3),55.5(7-OCH3),20.6,20.3,20.3,20.2(4C,Ac-CH3);ESI-MSm/z:673[M-H]-,675[M+H]+
实施例25
化合物12的合成
化合物6(90mg,0.118mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物78mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.51(s,1H,5-OH),9.24(s,1H,3′-OH),7.60(dd,J=9.0,2.4Hz,1H,H-6′),7.49(d,J=1.8Hz,1H,H-2′),7.01(d,J=9.0Hz,H-5′),6.40(d,J=1.8Hz,1H,H-8),6.19(d,J=1.8Hz,1H,H-6),5.62(d,J=7.8Hz,1H,H-1″),5.23-5.25(m,1H,H-5″),5.16-5.17(m,2H,H-2″,H-3″),4.15(t,J=18.6Hz,1H,H-4″),3.85(s,3H,4′-OCH3),3.80-3.82(m,2H,H-6″),2.12(s,3H,CH3CO),2.03(s,3H,CH3CO),1.91(s,3H,CH3CO),1.78(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.8,169.6,169.5,169.5(4C,Ac-CO),165.37(C-7),160.8(C-2),156.8(C-5),156.3(C-9),151.4(C-4′),147.9(C-3′),133.2(C-3),122.0(C-1′),121.9(C-6′),112.6(C-2′),111.1(C-5′),105.0(C-10),99.0(C-1″),98.1(C-6),92.6(C-8),70.3(C-2″),69.9(C-3″),68.9(C-4″),67.1(C-5″),60.7(C-6″),55.8(4′-OCH3),20.6,20.3,20.3,20.2(4C,Ac-CH3);ESI-MS m/z:645[M-H]-,647[M+H]+
实施例26
化合物13的合成
化合物8(60mg,0.118mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/甲醇=100∶0 to 5∶1)得黄色固体31mg,产率66.1%。1H-NMR(DMSO-d6,600MHz)δ:12.53(s,1H,5-OH),7.90(s,1H,H-2′),7.63(d,J=8.4Hz,1H,H-2′),7.09(d,J=8.4Hz,H-5′),6.73(s,1H,H-8),6.36(s,1H,H-6),5.56(d,J=7.2Hz,1H,H-1″),5.35(s,1H,4″-OH),5.05(s,1H,2″-OH),4.97(s,1H,3″-OH),4.39(s,1H,6″-OH),3.83(s,3H,4′-OCH3),3.82(s,3H,3′-OCH3),3.80(s,3H,7-OCH3),3.56(d,J=14.4Hz,1H,H-6″),3.08-3.22(m,5H,H-2″,H-3″,H-4″,H-5″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.6(C-4),165.2(C-7),162.0(C-2),156.4(C-5),156.4(C-9),151.1(C-4′),148.0(C-3′),133.6(C-3),122.4(C-1′),122.0(C-6′),112.7(C-2′),111.2(C-5′),105.1(C-10),100.7(C-1″),98.0(C-6),92.4(C-8),77.5(C-2″),76.4(C-3″),74.3(C-4″),69.8(C-5″),60.6(C-6″),56.2(7-OCH3),55.7(3′-OCH3),55.6(4′-OCH3);ESI-MS m/z:505[M-H]-,507[M+H]+
实施例27
化合物14的合成
化合物9(50mg,0.077mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/V甲醇=100∶0 to 5∶1)得黄色固体32mg,产率86.5%。1H-NMR(DMSO-d6,600MHz)δ:12.56(s,1H,5-OH),7.67(dd,J=8.4,2.4Hz,1H,H-6′),7.53(d,J=2.4Hz,1H,H-2′),7.02(d,J=8.4Hz,H-5′),6.38(s,1H,H-8),6.17(s,1H,H-6),5.46(d,J=9.0Hz,1H,H-1″),5.27(s,1H,4″-OH),5.05(s,1H,2″-OH),4.94(s,1H,3″-OH),4.26(s,1H,6″-OH),3.82(s,3H,4′-OCH3),3.55(m,1H,H-6″),3.06-3.19(m,5H,H-2″,H-3″,H-4″,H-5″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.49(C-4),164.46(C-7),161.3(C-2),156.4(C-5),155.8(C-9),150.3(C-4′),145.9(C-3′),133.60(C-3),122.7(C-1′),121.4(C-6′),115.7(C-2′),111.4(C-5′),104.0(C-10),100.8(C-1″),98.8(C-6),93.6(C-8),77.6(C-2″),76.5(C-3″),74.1(C-4″),80.0(C-5″),61.3(C-6″),55.7(4′-OCH3);ESI-MS m/z:477[M-H]-,479[M+H]+
实施例28
化合物15的合成
化合物11(50mg,0.077mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/甲醇=100∶0 to 5∶1)得黄色固体32mg,产率86.5%。1H-NMR(DMSO-d6,600MHz)δ:7.80(d,J=2.4Hz,1H,H-6′),7.64(d,J=9.0Hz,1H,H-2′),7.08(d,J=8.4Hz,H-5′),6.71(s,1H,H-8),6.35(s,1H,H-6),5.50(d,J=7.2Hz,1H,H-1″),5.18(s,1H,4″-OH),4.88(s,1H,2″-OH),4.53(s,1H,3″-OH),4.48(s,1H,6″-OH),3.84(s,3H,4′-OCH3),3.82(s,3H,3′-OCH3),3.81(s,3H,3-OCH3),3.65(m,1H,H-5″),3.54(t,J=16.2Hz,1H,H-3″),3.37-3.47(m,4H,H-2″,H-4″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.5(C-4),165.2(C-7),161.5(C-2),156.5(C-5),156.0(C-9),151.0(C-4′),148.0(C-3′),133.8(C-3),122.4(C-1′),121.7(C-6′),112.8(C-2′),111.1(C-5′),105.3(C-10),101.6(C-1″),98.1(C-6),92.0(C-8),76.0(C-2″),73.1(C-4″),71.3(C-4″),68.0(C-5″),60.3(C-6″),56.1(4′-OCH3),56.0(3′-OCH3),55.6(7-OCH3);ESI-MS m/z:505[M-H]-,507[M+H]+
实施例29
化合物16的合成
化合物12(50mg,0.077mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/甲醇=100∶0 to 5∶1)得黄色固体30mg,产率81.1%。1H-NMR(DMSO-d6,600MHz)δ:12.53(s,1H,5-OH),7.74(dd,J=2.4,1.8Hz,1H,H-6′),7.49(d,J=2.4Hz,1H,H-2′),6.97(d,J=9.0Hz,H-5′),6.35(s,1H,H-8),6.14(s,1H,H-6),5.36(d,J=7.2Hz,1H,H-1″),5.12(br-s,1H,4″-OH),4.83(br-s,1H,2″-OH),4.42(br-s,2H,3″-OH,6″-OH),3.82(s,3H,4′-OCH3),3.41-3.61(m,6H,H-2″,H-3″,H-4″,H-5″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.4(C-4),165.1(C-7),161.2(C-2),156.4(C-5),155.7(C-9),150.0(C-4′),146.0(C-3′),133.8(C-3),122.6(C-1′),121.7(C-6′),115.5(C-2′),111.3(C-5′),103.7(C-10),101.8(C-1″),99.0(C-6),93.7(C-8),75.9(C-2″),73.2(C-3″),71.2(C-4″),67.9(C-5″),60.2(C-6″),55.6(4′-OCH3);ESI-MS m/z:477[M-H]-,479[M+H]+
实施例30
化合物17的合成
化合物9(130mg,0.2mmol)溶于5mL干燥的DMF中,加入无水K2CO3(28mg,0.2mmol)和溴化苄(26μL,0.2mmol),于室温条件下搅拌24h后,加入30mL冰水,用3%稀盐酸调节PH值至中性,用乙酸乙酯萃取(30mL×3),合并有机层,有机层用饱和食盐水洗涤(50mL×2),无水MgSO4干燥,过滤,浓缩滤液,得黄色油状粗品,经硅胶柱色谱(环己烷/V乙酸乙酯=2∶1),得黄色油状物91mg,产率61.9%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),9.41(s,1H,3′-OH),7.61(d,J=2.4Hz,1H,H-2′),7.59(dd,J=6.6,1.8Hz,1H,H-6′),7.45(d,J=7.8Hz,2H,7-O-Bn-Ar),7.39(t,J=15.6Hz,2H,7-O-Bn-Ar),7.35(t,J=14.4Hz,1H,7-O-Bn-Ar),7.04(d,J=8.4Hz,1H,H-5′),6.83(d,J=1.8Hz,1H,H-8),6.46(d,J=1.8Hz,1H,H-6),5.68(d,J=7.8Hz,1H,H-1″),5.34(t,J=19.2Hz,1H,H-6″),5.22(s,2H,5-O-Bn-CH2),5.12(t,J=17.4Hz,1H,H-6″),4.98(t,J=19.2Hz,1H,H-5″),3.86-3.95(m,3H,H-3″,H-2″,H-4″),3.84(s,3H,4′-OCH3),2.01(s,3H,CH3CO),1.95(s,3H,CH3CO),1.94(s,3H,CH3CO),1.80(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.8,169.5,169.34,169.3(4C,Ac-CO),164.4(C-7),160.9(C-2),157.2(C-5),156.3(C-9),150.5(C-4′),145.9(C-3′),136.1(7-O-Bn-Ar),133.3(C-3),127.9-128.6(5C,7-O-Bn-Ar),121.9(C-1′),121.1(C-6′),116.1(C-2′),111.3(C-5′),105.1(C-10),98.7(C-1″),98.6(C-6),93.3(C-8),71.9(C-3″),71.4(C-2″),70.6(C-5″),67.8(C-4″),61.0(C-6″),55.6(4′-OCH3),20.5,20.4,20.3,20.1(4C,Ac-CH3);ESI-MS m/z:735[M-H]-,737[M+]+
实施例31
化合物18的合成
化合物12(150mg,0.23mmol)溶于5mL干燥的DMF中,加入无水K2CO3(32mg,0.23mmol)和溴化苄(30μL,0.2mmol),于室温条件下搅拌24h后,加入30mL冰水,用3%稀盐酸调节PH值至中性,用乙酸乙酯萃取(30mL×3),合并有机层,有机层用饱和食盐水洗涤(50mL×2),无水MgSO4干燥,过滤,浓缩滤液,得黄色油状粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得黄色油状物94mg,产率55%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),9.24(s,1H,3′-OH),7.62(dd,J=8.4,2.4Hz,1H,H-6′),7.53(d,J=2.4Hz,1H,H-2′),7.44(d,J=7.2Hz,2H,Bn-Ar-H-2,Bn-Ar-H-6),739(t,J=15.0Hz,2H,Bn-Ar-H-3,Bn-Ar-H-5),7.33(t,J=14.4Hz,1H,Bn-Ar-H-5),7.04(d,J=9.0Hz,1H,H-5′),6.81(d,J=1.8Hz,1H,H-8),6.45(d,J=2.4Hz,1H,H-6),5.62(d,J=7.8Hz,1H,H-1″),5.24-5.26(m,1H,H-6″),5.22(s,2H,7-O-Bn-CH2),5.17-5.20(m,2H,H-5″,H-6″),4.17(m,1H,H-2″),3.85(s,3H,4′-OCH3),3.82-3.84(m,2H,H-3″,H-4″),2.12(s,3H,CH3CO),2.03(s,3H,CH3CO),1.91(s,3H,CH3CO),1.76(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.1(C-4),170.0,169.5,169.5,169.4(4C,Ac-CO),164.3(C-7),160.9(C-2),157.3(C-5),156.3(C-9),150.4(C-4′),146.0(C-3′),136.1(Bn-Ar-C-1),133.4(C-3),128.6(2C,7-O-Bn-Ar-C-3,5),128.2(7-O-Bn-Ar-C-4),127.9(7-O-Bn-Ar-C-2,6),122.2(C-1′),121.4(C-6′),116.0(C-2′),111.2(C-5′),105.1(C-10),98.9(C-1″),98.7(C-6),93.3(C-8),70.2(2C,7-O-Bn-CH2,C-2″),70.1(C-3″),69.2(C-5″),67.1(C-4″),60.9(C-6″),55.7(4′-OCH3),20.6,20.,20.4,20.2(4C,Ac-CH3);ESI-MS m/z:735[M-H]-,737[M+H]+
实施例32
药理学实验:
用十万分之一天平精密称取样品,然后用DMSO溶解成适合的浓度作为贮备液,在-20℃下保存,使用前再用SUM149细胞培养液稀释成所需的浓度。
常法培养SUM149细胞,待其增殖至细胞交联70-80%时,吸去培养基,加入2mL0.25%胰蛋白酶溶液,放入37℃、5%CO2培养箱消化2-3min,至显微镜下观察大部分细胞已不再贴壁,加入6mL培养基终止消化,得到细胞混悬液,于500rpm的低温离心机内离心3min,吸去上清液,重新加入6mL培养基,吹散细胞,测定细胞密度。将细胞密度调整至3×103/孔,接种于96孔板,放于37℃、5%CO2培养箱培养24h,随后加待测试样品,实验分组为:空白组和不同剂量组,根据前期预试验,每个化合物测试4个浓度,每个浓度3个复孔,每孔200μL培养液。加毕,放于37℃、5%CO2培养箱培养48h后,吸去培养液,加入新鲜配制MTS试剂,置于37℃培养箱2h,置于酶标仪490nm处测OD值,读数转到Graphpad Prism软件计算IC50等数值。
结果表明(如表2所示):化合物1b-1m、1、3表现出较强的对人三阴性乳腺癌细胞的生长抑制作用,其IC50值范围为1.38-11.98μM;而其余的化合物则无明显细胞毒活性,在最大测试浓度(20μM)下的抑制率<50%。
表2化合物1b-1m、1、3对人三阴性乳腺癌细胞系
SUM 149的生长抑制作用(n=3)
Figure BSA0000214446230000371

Claims (5)

1.一个黄酮类化合物,其特征在于,结构式如下:
Figure FSA0000214446220000011
2.一个黄酮类化合物,其特征在于,结构式如下:
Figure FSA0000214446220000012
3.一个黄酮类化合物,其特征在于,结构式如下:
Figure FSA0000214446220000013
4.如权利要求1-3所述黄酮类化合物在制备抗炎药物方面的用途。
5.结构式如下的黄酮类化合物在制备抗炎药物方面的用途:
Figure FSA0000214446220000021
CN202010701196.2A 2020-07-20 2020-07-20 黄酮类化合物及其合成方法和用途 Pending CN113956227A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010701196.2A CN113956227A (zh) 2020-07-20 2020-07-20 黄酮类化合物及其合成方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010701196.2A CN113956227A (zh) 2020-07-20 2020-07-20 黄酮类化合物及其合成方法和用途

Publications (1)

Publication Number Publication Date
CN113956227A true CN113956227A (zh) 2022-01-21

Family

ID=79459493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010701196.2A Pending CN113956227A (zh) 2020-07-20 2020-07-20 黄酮类化合物及其合成方法和用途

Country Status (1)

Country Link
CN (1) CN113956227A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110804056A (zh) * 2019-11-06 2020-02-18 浙江工业大学 具有金雀花碱-黄酮类骨架的化合物及其合成方法与应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110804056A (zh) * 2019-11-06 2020-02-18 浙江工业大学 具有金雀花碱-黄酮类骨架的化合物及其合成方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASHA SRINIVASAN等: "Quercetin Regulates β-Catenin Signaling and Reduces the Migration of Triple Negative Breast Cancer", 《MOLECULAR CARCINOGENESIS》, vol. 55, 12 May 2015 (2015-05-12), pages 743 *

Similar Documents

Publication Publication Date Title
US3524844A (en) Epipodophyllotoxin glucoside derivatives
CN101671375B (zh) 一种溴代四乙酰葡萄糖及其合成方法与它的用途
Abe et al. Trypanocidal constituents in plants 6. Minor withanolides from the aerial parts of Physalis angulata
Kouno et al. Two new iridolactones and their glycosides from the roots of Patrinia scabra
US3408441A (en) Epipodophyllotoxin-beta-d-glucosides and derivatives thereof
CN113387915B (zh) 一种桉烷型倍半萜内酯类tbb衍生物及其制备方法、用途
AU2020103289A4 (en) Preparation and Application of Alkaloid Derivatives for Reversing Human Tumor Drug Resistance and Anti-canine Breast Cancer
CN103992333B (zh) 色原酮二聚体衍生物及其制备方法和用途
CN102086219A (zh) 具有抗癌活性的蒽环类抗生素简单结构类似物及制备方法
CN105503804A (zh) 槲皮素-3-o-乙酸酯的合成及在抗肿瘤方面的应用
CN113956227A (zh) 黄酮类化合物及其合成方法和用途
Chen et al. Bauhinin, a new nitrile glucoside from Bauhinia championii
CN110117307B (zh) 楤木皂苷衍生物及其制备方法和用途
JP2006206489A (ja) 抗癌剤
CN115073406B (zh) 一种桉烷型倍半萜内酯类tba衍生物及其用途
EP2716293B1 (en) Anti-tumor agent
CN115057839B (zh) 一种桉烷型倍半萜烯内酯化合物及其制备和用途
CN113956224A (zh) 半合成黄酮类化合物及其抗炎用途
NISHIMURA et al. Tannins and Related Compounds. XLVI.: Isolation and Structures of Stenophynins A and B, Novel Tannins from Quercus stenophylla MAKINO
Zhou et al. Biotransformation of 4-phenylcoumarin by transgenic hairy roots of Polygonum multiflorum
Hossain et al. A new flavonol glycoside from the seeds of Zea Mays
CN103570780B (zh) 鬼臼毒素糖苷物和酰化糖苷物及其药物组合物和其制备方法与应用
Sakurai et al. Chemical studies on the mistletoe. V. The structure of taxillusin, a new flavonoid glycoside isolated from Taxillus kaempferi.
CN111995647B (zh) 从绿萼梅中分离的具有抗肿瘤活性的化合物及其制备方法
CN100506777C (zh) 一类具有抗癌活性的苯并双萘醌衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination